Stereotactic Radiation Therapy Versus Standard Palliative Care for Oligometastatic Tumors in Various Organs

What this Trial Is About

Researchers are evaluating stereotactic radiation therapy as a treatment for patients with oligometastatic cancer, which means having one to five metastatic tumors in bones or internal organs. The study aims to improve treatment effectiveness compared to the usual palliative care, which includes chemotherapy and less intense radiation therapy. This trial includes adult patients with various tumor locations who have completed a current chemotherapy line and have specific cancer stages T1-4, N0-3, M0-1. Participants are randomly assigned to receive either stereotactic ablative radiation therapy targeting each metastatic site or standard palliative radiation therapy or chemotherapy alone. The stereotactic radiation uses detailed imaging and planning to deliver focused, high-dose radiation over several sessions depending on tumor location and size. The study involves pre-treatment imaging and planning, radiation treatment sessions lasting from one to eight working days, and follow-up visits scheduled at 3, 6, 9, 12, 18, and 24 months. During the study, participants undergo comprehensive examinations before treatment, imaging scans, and radiation sessions with precise targeting methods. Researchers will monitor progression-free survival and time before changing chemotherapy lines as primary outcomes, along with side effects, overall survival, metastasis control, and quality of life assessments. Data collection and analysis will continue through follow-up visits extending up to two years after treatment completion.

Stereotactic Radiotherapy for Oligometastasis (1-5) in Various Tumor Sites vs. Palliative Care